\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ was\\ within\\ normal\\ limits\\ at\\ the\\ time\\ of\\ study\\.\\ \\ no\\ neurological\\ deficits\\ were\\ noted\\,\\ nor\\ were\\ there\\ any\\ residual\\ deficits\\ from\\ the\\ suspected\\ prior\\ event\\ at\\ age\\ 5\\.\ \(0\)\
\-\ hemoglobin\\ electrophoresis\\:\\ \ \(0\)\
\-\ hgs\\ 25\\.6\\ \\%\\,\\ hga2\\ 3\\.2\\%\\,\\ hgf\\ 1\\.7\\ \\%\\,\\ hga\\ 69\\.2\\%\ \(0\)\
\-\ cbc\\:\\ \\ wbc\\ 12\\.0\\,\\ hgb\\ 10\\.0\\,\\ hct\\ 28\\.5\\,\\ plt\\ 303\ \(0\)\
\-\ treatment\\ of\\ moyamoya\\ is\\ directed\\ at\\ the\\ complications\\.\\ \\ if\\ an\\ intracerebral\\ hemorrhage\\ has\\ occurred\\,\\ managment\\ of\\ hypertension\\ is\\ warranted\\.\\ \\ if\\ ischemia\\ has\\ occurred\\,\\ anticoagulation\\ and\\/or\\ antithrombotic\\ therapy\\ should\\ be\\ considered\\.\ \(0\)\
\-\ patients\\ who\\ present\\ for\\ treatment\\ while\\ symptoms\\ are\\ evolving\\ have\\ a\\ better\\ prognosis\\ than\\ those\\ who\\ present\\ with\\ static\\ symptoms\\.\ \(0\)\
\-\ various\\ surgical\\ procedures\\ have\\ been\\ used\\:\\ superficial\\ temporal\\ artery\\â\\€\\“middle\\ cerebral\\ artery\\ \\(sta\\-mca\\)\\ anastomosis\\,\\ encephaloduroarteriosynangiosis\\ \\(edas\\)\\,\\ encephaloduroarteriomyosynangiosis\\ \\(edams\\)\\,\\ pial\\ synangiosis\\,\\ and\\ omental\\ transplantation\\ to\\ the\\ cns\\.\ \(0\)\
\-\ there\\ is\\ significant\\ vasculopathy\\ compatible\\ with\\ sickle\\ cell\\ disease\\.\\ \\ there\\ is\\ severe\\ narrowing\\ of\\ the\\ cavernous\\ and\\ supraclinoid\\ portions\\ of\\ the\\ left\\ internal\\ carotid\\ artery\\ and\\ narrowing\\ at\\ the\\ origins\\ of\\ the\\ left\\ a1\\ and\\ left\\ m1\\ segments\\ of\\ the\\ internal\\ carotid\\ artery\\.\\ \\ the\\ left\\ middle\\ cerebral\\ artery\\ appears\\ attenuated\\.\\ \\ there\\ is\\ diminished\\ flow\\ identified\\ at\\ and\\ distal\\ to\\ the\\ trifurcation\\ of\\ the\\ left\\ middle\\ cerebral\\ artery\\.\\ \\ \ \(0\)\
\-\ moyamoya\\ collateral\\ vessels\\ are\\ again\\ identified\\ in\\ the\\ left\\ basal\\ ganglia\\ region\\ and\\ also\\ at\\ the\\ region\\ of\\ the\\ bifurcation\\ of\\ the\\ left\\ internal\\ carotid\\ artery\\ and\\ the\\ right\\ cerebral\\ peduncle\\ region\\.\\ \ \(0\)\
\-\ the\\ anterior\\ and\\ posterior\\ branches\\ of\\ the\\ middle\\ menigeal\\ arteries\\ appear\\ more\\ prominent\\,\\ reflecting\\ collateral\\ supply\\ from\\ the\\ external\\ carotid\\ circulation\\.\ \(0\)\
\-\ moyamoya\\ disease\\ secondary\\ to\\ sickle\\ cell\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ anterior\\ circulation\\ stroke\ \(1\)\
\-\ \\â\\€\\¢\\ basilar\\ artery\\ thrombosis\ \(1\)\
\-\ \\â\\€\\¢\\ blood\\ dyscrasias\ \(1\)\
\-\ \\â\\€\\¢\\ moya\\-moya\\ disease\ \(0\)\
\-\ 19\\ year\\ old\\ with\\ sickle\\ cell\\ disease\\.\\ \\ at\\ 5\\ years\\ of\\ age\\,\\ he\\ presented\\ with\\ dysarthria\\,\\ confusion\\,\\ and\\ mild\\ right\\ hemiparesis\\;\\ and\\,\\ had\\ an\\ apparently\\ normal\\ mri\\ at\\ this\\ time\\.\\ between\\ the\\ ages\\ of\\ 5\\ and\\ 19\\,\\ he\\ has\\ not\\ had\\ any\\ symptomatic\\ vascular\\ events\\.\\ \\ he\\ presents\\ now\\ for\\ follow\\ up\\ and\\ screening\\ exam\\ for\\ cerebrovascular\\ pathology\\.\ \(0\)\
\-\ this\\ patient\\ has\\ significant\\ vasculopathy\\ with\\ some\\ new\\ development\\ of\\ collateralization\\.\\ \\ there\\ is\\ increased\\ signal\\ within\\ the\\ frontal\\ lobes\\ implying\\ low\\ grade\\ chronic\\ ischemia\\.\\ \\ these\\ findings\\ can\\ manifest\\ as\\ problems\\ with\\ executive\\ functioning\\,\\ planning\\ and\\ organizing\\ and\\ can\\ effect\\ activities\\ of\\ daily\\ living\\.\\ \\ in\\ this\\ patient\\ asynangiosis\\ procedure\\ is\\ being\\ considered\\,\\ as\\ well\\ as\\,\\ a\\ diamox\\ challenge\\ scan\\ to\\ fully\\ assess\\ candidacy\\.\\ \\ he\\ has\\ been\\ on\\ chronic\\ blood\\ tranfusions\\ with\\ the\\ hope\\ of\\ preventing\\ further\\ significant\\ cerebrovascular\\ events\\.\ \(0\)\
\-\ of\\ note\\,\\ a\\ study\\ reported\\ in\\ blood\\,\\ 1\\ may\\ 2002\\,\\ noted\\ that\\ \\'chronic\\ transfusions\\ are\\ effective\\ in\\ preventing\\ the\\ recurrance\\ of\\ infarctive\\ strokes\\ in\\ sickle\\ cell\\ disease\\ \\(scd\\)\\.\\ \\ the\\ reasons\\ why\\ some\\ patients\\ develop\\ recurrances\\ while\\ complying\\ with\\ transfusions\\ are\\ unknown\\.\\'\\ \\ this\\ study\\ reported\\ that\\ 41\\%\\ of\\ scd\\ patients\\ had\\ a\\ recurrent\\ cerebrovascular\\ event\\ even\\ with\\ compliant\\ transfusion\\ therapy\\.\\ \\ in\\ addition\\,\\ \\'patients\\ with\\ moyamoya\\ collaterals\\ were\\ found\\ to\\ be\\ at\\ higher\\ risk\\ for\\ recurrent\\ strokes\\ and\\ tias\\ compared\\ with\\ patients\\ without\\ these\\ collaterals\\.\\'\\ \\ the\\ authors\\ mentioned\\ some\\ therapy\\ options\\ which\\ this\\ patient\\ is\\ currently\\ not\\ utilizing\\:\\ \\ hydroxyurea\\ and\\ phlebotomy\\ and\\ bone\\ marrow\\ transplantation\\,\\ all\\ as\\ options\\ to\\ decrease\\ the\\ risk\\ of\\ future\\ cva\\,\\ as\\ well\\ as\\,\\ prevention\\ of\\ worsening\\ neuropsychological\\ complications\\ due\\ to\\ poor\\ perfusion\\.\\ \\ blood\\,\\ 1\\ may\\ 2002\\.\\ volume\\ 99\\.\\ \\ number\\ 9\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ moyamoya\\:\\ 0\\.04871622336292857\ \(0\)\
\-\ cerebrovascular\\:\\ 0\\.032548986130968585\ \(0\)\
\-\ sickle\\:\\ 0\\.030958517126192773\ \(0\)\
\-\ artery\\:\\ 0\\.02919952449960228\ \(0\)\
\-\ scd\\:\\ 0\\.025301331591142256\ \(0\)\
\-\ carotid\\:\\ 0\\.0251272905066109\ \(0\)\
\-\ vasculopathy\\:\\ 0\\.02362649348043409\ \(0\)\
\-\ strokes\\:\\ 0\\.02169932408731239\ \(0\)\
\-\ collaterals\\:\\ 0\\.019614115016099287\ \(0\)\
\-\ transfusions\\:\\ 0\\.01942671038055847\ \(0\)\
\-\ cerebral\\:\\ 0\\.019412763945993908\ \(0\)\
\-\ preventing\\:\\ 0\\.019081266066926252\ \(0\)\
\-\ events\\:\\ 0\\.018921298315551064\ \(0\)\
\-\ transplantation\\:\\ 0\\.01862303019028639\ \(0\)\
\-\ at\\:\\ 0\\.017081751435220817\ \(0\)\
\-\ circulation\\:\\ 0\\.01706426397154844\ \(0\)\
\-\ \\%\\:\\ 0\\.01633869699463941\ \(0\)\
\-\ he\\:\\ 0\\.01563401535759357\ \(0\)\
\-\ event\\:\\ 0\\.015479258563096386\ \(0\)\
\-\ middle\\:\\ 0\\.015369634276930022\ \(0\)\
\-\ blood\\:\\ 0\\.015294498836126554\ \(0\)\
\-\ cell\\:\\ 0\\.015136004666108106\ \(0\)\
\-\ occurred\\:\\ 0\\.014836258960059369\ \(0\)\
\-\ collateral\\:\\ 0\\.014661354105287915\ \(0\)\
\-\ patients\\:\\ 0\\.014502128520432957\ \(0\)\
\-\ hgs\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ hga2\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ hgf\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ hga\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ 69\\.2\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ 303\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ antithrombotic\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ artery\\â\\€\\“middle\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ sta\\-mca\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ encephaloduroarteriosynangiosis\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ edas\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ encephaloduroarteriomyosynangiosis\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ edams\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ synangiosis\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ menigeal\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ asynangiosis\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ diamox\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ \\'chronic\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ infarctive\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ recurrances\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ complying\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ \\'patients\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ hydroxyurea\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ phlebotomy\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ neuropsychological\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ 99\\.\\:\\ 0\\.014451669547486062\ \(0\)\
\-\ \\'\\:\\ 0\\.014223546260617349\ \(0\)\
\-\ internal\\:\\ 0\\.014089553465797237\ \(0\)\
\-\ study\\:\\ 0\\.013827695197671932\ \(0\)\
\-\ disease\\:\\ 0\\.013738402044744632\ \(0\)\
\-\ options\\:\\ 0\\.013613374851981743\ \(0\)\
\-\ 28\\.5\\:\\ 0\\.013315362694109103\ \(0\)\
\-\ executive\\:\\ 0\\.013315362694109103\ \(0\)\
\-\ candidacy\\:\\ 0\\.013315362694109103\ \(0\)\
\-\ tranfusions\\:\\ 0\\.013315362694109103\ \(0\)\
\-\ \\,\\:\\ 0\\.013313609779538724\ \(0\)\
\-\ has\\:\\ 0\\.01315327844667441\ \(0\)\
\-\ ischemia\\:\\ 0\\.013020758483632482\ \(0\)\
\-\ 19\\:\\ 0\\.012919085576279824\ \(0\)\
\-\ deficits\\:\\ 0\\.012820470968944488\ \(0\)\
\-\ some\\:\\ 0\\.012761942232131604\ \(0\)\
\-\ as\\:\\ 0\\.012713877107155356\ \(0\)\
\-\ 25\\.6\\:\\ 0\\.012650665795571128\ \(0\)\
\-\ dyscrasias\\:\\ 0\\.012650665795571128\ \(0\)\
\-\ recurrance\\:\\ 0\\.012650665795571128\ \(0\)\
\-\ managment\\:\\ 0\\.012179055840732143\ \(0\)\
\-\ trifurcation\\:\\ 0\\.012179055840732143\ \(0\)\
\-\ moya\\-moya\\:\\ 0\\.012179055840732143\ \(0\)\
\-\ compliant\\:\\ 0\\.012179055840732143\ \(0\)\
\-\ region\\:\\ 0\\.011870169970029407\ \(0\)\
\-\ recurrent\\:\\ 0\\.011823056626639598\ \(0\)\
\-\ 12\\.0\\:\\ 0\\.011813246740217045\ \(0\)\
\-\ 10\\.0\\:\\ 0\\.011813246740217045\ \(0\)\
\-\ a1\\:\\ 0\\.011813246740217045\ \(0\)\
\-\ electrophoresis\\:\\ 0\\.011514358942194169\ \(0\)\
\-\ supraclinoid\\:\\ 0\\.011514358942194169\ \(0\)\
\-\ implying\\:\\ 0\\.011514358942194169\ \(0\)\
\-\ considered\\:\\ 0\\.011309975111293924\ \(0\)\
\-\ significant\\:\\ 0\\.011300887628135525\ \(0\)\
\-\ origins\\:\\ 0\\.011261652909690468\ \(0\)\
\-\ m1\\:\\ 0\\.011261652909690468\ \(0\)\
\-\ reflecting\\:\\ 0\\.011261652909690468\ \(0\)\
\-\ tias\\:\\ 0\\.011261652909690468\ \(0\)\
\-\ therapy\\:\\ 0\\.01123593834216695\ \(0\)\
\-\ narrowing\\:\\ 0\\.0112342514562295\ \(0\)\
\-\ complications\\:\\ 0\\.011102205885285434\ \(0\)\
\-\ collateralization\\:\\ 0\\.011042748987355184\ \(0\)\
\-\ hope\\:\\ 0\\.011042748987355184\ \(0\)\
\-\ left\\:\\ 0\\.010971699811328528\ \(0\)\
\-\ pial\\:\\ 0\\.010849662043656194\ \(0\)\
\-\ organizing\\:\\ 0\\.010849662043656194\ \(0\)\
\-\ challenge\\:\\ 0\\.010849662043656194\ \(0\)\
\-\ evolving\\:\\ 0\\.010520693690439554\ \(0\)\
\-\ there\\:\\ 0\\.010423898003811383\ \(0\)\
\-\ peduncle\\:\\ 0\\.01037805208881721\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.010275503944891068\ \(0\)\
\-\ attenuated\\:\\ 0\\.010246834535254035\ \(0\)\
\-\ reported\\:\\ 0\\.010213360165822334\ \(0\)\
\-\ risk\\:\\ 0\\.010148218515931432\ \(0\)\
\-\ 2002\\.\\:\\ 0\\.010125346056313508\ \(0\)\
\-\ intracerebral\\:\\ 0\\.010012242988302111\ \(0\)\
\-\ prevention\\:\\ 0\\.010012242988302111\ \(0\)\
\-\ identified\\:\\ 0\\.010011367348151874\ \(0\)\
\-\ why\\:\\ 0\\.009807057508049643\ \(0\)\
\-\ 3\\.2\\:\\ 0\\.009713355190279235\ \(0\)\
\-\ static\\:\\ 0\\.009713355190279235\ \(0\)\
\-\ anastomosis\\:\\ 0\\.009713355190279235\ \(0\)\
\-\ dysarthria\\:\\ 0\\.009713355190279235\ \(0\)\
\-\ manifest\\:\\ 0\\.00962472040131157\ \(0\)\
\-\ utilizing\\:\\ 0\\.00962472040131157\ \(0\)\
\-\ were\\:\\ 0\\.009542391819786498\ \(0\)\
\-\ transfusion\\:\\ 0\\.009460649157775532\ \(0\)\
\-\ cva\\:\\ 0\\.009460649157775532\ \(0\)\
\-\ omental\\:\\ 0\\.009384386837062594\ \(0\)\
\-\ authors\\:\\ 0\\.009384386837062594\ \(0\)\
\-\ living\\:\\ 0\\.009311515095143195\ \(0\)\
\-\ apparently\\:\\ 0\\.009174823932948028\ \(0\)\
\-\ functioning\\:\\ 0\\.009110527681877074\ \(0\)\
\-\ had\\:\\ 0\\.009068113865118238\ \(0\)\
\-\ planning\\:\\ 0\\.00904865829174126\ \(0\)\
\-\ plt\\:\\ 0\\.00893151244914758\ \(0\)\
\-\ warranted\\:\\ 0\\.008875936134925152\ \(0\)\
\-\ any\\:\\ 0\\.008822409944499324\ \(0\)\
\-\ 1\\.7\\:\\ 0\\.00882218232701861\ \(0\)\
\-\ while\\:\\ 0\\.008815243409351848\ \(0\)\
\-\ hemiparesis\\:\\ 0\\.008719689938524618\ \(0\)\
\-\ activities\\:\\ 0\\.008670750654672684\ \(0\)\
\-\ hemoglobin\\:\\ 0\\.00853213198577422\ \(0\)\
\-\ bifurcation\\:\\ 0\\.00853213198577422\ \(0\)\
\-\ age\\:\\ 0\\.008527574837850185\ \(0\)\
\-\ fully\\:\\ 0\\.008488413547934611\ \(0\)\
\-\ confusion\\:\\ 0\\.008404326180086167\ \(0\)\
\-\ directed\\:\\ 0\\.008363846487315066\ \(0\)\
\-\ mentioned\\:\\ 0\\.008363846487315066\ \(0\)\
\-\ reasons\\:\\ 0\\.008324342304398573\ \(0\)\
\-\ 5\\:\\ 0\\.008197247286702175\ \(0\)\
\-\ effective\\:\\ 0\\.007974220828500115\ \(0\)\
\-\ perfusion\\:\\ 0\\.007974220828500115\ \(0\)\
\-\ ages\\:\\ 0\\.007942994279367831\ \(0\)\
\-\ time\\:\\ 0\\.007913446646686272\ \(0\)\
\-\ chronic\\:\\ 0\\.007891769288219672\ \(0\)\
\-\ segments\\:\\ 0\\.007882270883170537\ \(0\)\
\-\ this\\:\\ 0\\.007878173879624042\ \(0\)\
\-\ hgb\\:\\ 0\\.007795205595770622\ \(0\)\
\-\ supply\\:\\ 0\\.007795205595770622\ \(0\)\
\-\ future\\:\\ 0\\.007767181934525866\ \(0\)\
\-\ various\\:\\ 0\\.007739629281548193\ \(0\)\
\-\ compatible\\:\\ 0\\.007739629281548193\ \(0\)\
\-\ diminished\\:\\ 0\\.0076596454058606\ \(0\)\
\-\ branches\\:\\ 0\\.0076596454058606\ \(0\)\
\-\ 2002\\:\\ 0\\.0076596454058606\ \(0\)\
\-\ are\\:\\ 0\\.0076385171969154215\ \(0\)\
\-\ been\\:\\ 0\\.007622278326111447\ \(0\)\
\-\ hct\\:\\ 0\\.007608411727985018\ \(0\)\
\-\ if\\:\\ 0\\.007602437487805362\ \(0\)\
\-\ procedures\\:\\ 0\\.00758338308514766\ \(0\)\
\-\ nor\\:\\ 0\\.00748692324904449\ \(0\)\
\-\ superficial\\:\\ 0\\.00748692324904449\ \(0\)\
\-\ 41\\:\\ 0\\.007463669749057677\ \(0\)\
\-\ \\:\\:\\ 0\\.007411638137643705\ \(0\)\
\-\ is\\:\\ 0\\.007374305290291484\ \(0\)\
\-\ basilar\\:\\ 0\\.007352106694557652\ \(0\)\
\-\ stroke\\:\\ 0\\.007309523929962142\ \(0\)\
\-\ who\\:\\ 0\\.007304814456202301\ \(0\)\
\-\ these\\:\\ 0\\.007291294071992918\ \(0\)\
\-\ portions\\:\\ 0\\.007288640281146683\ \(0\)\
\-\ daily\\:\\ 0\\.007247654539826327\ \(0\)\
\-\ better\\:\\ 0\\.007227539633938107\ \(0\)\
\-\ anterior\\:\\ 0\\.00721571417627127\ \(0\)\
\-\ cns\\:\\ 0\\.0071686347007806255\ \(0\)\
\-\ ganglia\\:\\ 0\\.0071686347007806255\ \(0\)\
\-\ anticoagulation\\:\\ 0\\.007074932383010218\ \(0\)\
\-\ assess\\:\\ 0\\.007021178575103675\ \(0\)\
\-\ develop\\:\\ 0\\.006986297594042554\ \(0\)\
\-\ number\\:\\ 0\\.006986297594042554\ \(0\)\
\-\ symptoms\\:\\ 0\\.0069824835308135704\ \(0\)\
\-\ residual\\:\\ 0\\.006952143353218222\ \(0\)\
\-\ higher\\:\\ 0\\.006869746902757749\ \(0\)\
\-\ again\\:\\ 0\\.0067311282338592855\ \(0\)\
\-\ 1\\:\\ 0\\.0066666438293760885\ \(0\)\
\-\ prognosis\\:\\ 0\\.006644827031424167\ \(0\)\
\-\ noted\\:\\ 0\\.006640725208041291\ \(0\)\
\-\ volume\\:\\ 0\\.006617040870254047\ \(0\)\
\-\ cavernous\\:\\ 0\\.0064975215738473455\ \(0\)\
\-\ problems\\:\\ 0\\.006484763966565288\ \(0\)\
\-\ decrease\\:\\ 0\\.006410235484472244\ \(0\)\
\-\ basal\\:\\ 0\\.0063861270461284805\ \(0\)\
\-\ those\\:\\ 0\\.0063742044898513015\ \(0\)\
\-\ can\\:\\ 0\\.0063548273851444905\ \(0\)\
\-\ well\\:\\ 0\\.006337970337602135\ \(0\)\
\-\ present\\:\\ 0\\.006327897553874363\ \(0\)\
\-\ poor\\:\\ 0\\.0063044346301483565\ \(0\)\
\-\ cbc\\:\\ 0\\.0062595182790203\ \(0\)\
\-\ even\\:\\ 0\\.006237513327656135\ \(0\)\
\-\ lobes\\:\\ 0\\.006173217076585183\ \(0\)\
\-\ marrow\\:\\ 0\\.006162741997734738\ \(0\)\
\-\ exam\\:\\ 0\\.0061548653768837315\ \(0\)\
\-\ may\\:\\ 0\\.006145338914420078\ \(0\)\
\-\ the\\:\\ 0\\.006119230634422781\ \(0\)\
\-\ development\\:\\ 0\\.006101259382229075\ \(0\)\
\-\ have\\:\\ 0\\.006067010093000301\ \(0\)\
\-\ neurological\\:\\ 0\\.006061515756638923\ \(0\)\
\-\ 5\\.\\:\\ 0\\.006041999523022008\ \(0\)\
\-\ suspected\\:\\ 0\\.006032327847403666\ \(0\)\
\-\ thrombosis\\:\\ 0\\.006013154011726304\ \(0\)\
\-\ screening\\:\\ 0\\.005975466276931716\ \(0\)\
\-\ external\\:\\ 0\\.005956942415859694\ \(0\)\
\-\ addition\\:\\ 0\\.005938625529633259\ \(0\)\
\-\ compared\\:\\ 0\\.005929543266722414\ \(0\)\
\-\ and\\/or\\:\\ 0\\.00592051104408148\ \(0\)\
\-\ procedure\\:\\ 0\\.0058673384608795886\ \(0\)\
\-\ arteries\\:\\ 0\\.005799022565140952\ \(0\)\
\-\ 9\\:\\ 0\\.005790679828243459\ \(0\)\
\-\ limits\\:\\ 0\\.005774120654495092\ \(0\)\
\-\ prominent\\:\\ 0\\.005749591355025071\ \(0\)\
\-\ appear\\:\\ 0\\.00573344004938079\ \(0\)\
\-\ pathology\\:\\ 0\\.00573344004938079\ \(0\)\
\-\ treatment\\:\\ 0\\.005670875277379957\ \(0\)\
\-\ vessels\\:\\ 0\\.005639737731610382\ \(0\)\
\-\ temporal\\:\\ 0\\.005609657176416618\ \(0\)\
\-\ symptomatic\\:\\ 0\\.005565546597859364\ \(0\)\
\-\ currently\\:\\ 0\\.005551102942642717\ \(0\)\
\-\ hypertension\\:\\ 0\\.005522591889016702\ \(0\)\
\-\ worsening\\:\\ 0\\.005515540935083275\ \(0\)\
\-\ unknown\\:\\ 0\\.005467015574794273\ \(0\)\
\-\ note\\:\\ 0\\.005406664799183263\ \(0\)\
\-\ used\\:\\ 0\\.005374072388439281\ \(0\)\
\-\ within\\:\\ 0\\.005344693142249448\ \(0\)\
\-\ grade\\:\\ 0\\.005335798021231099\ \(0\)\
\-\ appears\\:\\ 0\\.005214309542290571\ \(0\)\
\-\ wbc\\:\\ 0\\.005106680082911167\ \(0\)\
\-\ and\\:\\ 0\\.005016644422045432\ \(0\)\
\-\ effect\\:\\ 0\\.004959931562408598\ \(0\)\
\-\ to\\:\\ 0\\.004900781572296563\ \(0\)\
\-\ new\\:\\ 0\\.004881619634099276\ \(0\)\
\-\ being\\:\\ 0\\.004881619634099276\ \(0\)\
\-\ that\\:\\ 0\\.0048392810772420435\ \(0\)\
\-\ now\\:\\ 0\\.00478871408147811\ \(0\)\
\-\ for\\:\\ 0\\.004781037040280099\ \(0\)\
\-\ \\(\\:\\ 0\\.004736798204877774\ \(0\)\
\-\ \\)\\:\\ 0\\.004678935685988886\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.004662715711763993\ \(0\)\
\-\ flow\\:\\ 0\\.00462959651944019\ \(0\)\
\-\ vascular\\:\\ 0\\.004593120111350322\ \(0\)\
\-\ should\\:\\ 0\\.004465915642440655\ \(0\)\
\-\ further\\:\\ 0\\.004454826461967636\ \(0\)\
\-\ follow\\:\\ 0\\.004451146675322023\ \(0\)\
\-\ between\\:\\ 0\\.004440156616761055\ \(0\)\
\-\ found\\:\\ 0\\.0044147960892657575\ \(0\)\
\-\ frontal\\:\\ 0\\.004400478581120258\ \(0\)\
\-\ normal\\:\\ 0\\.004392171982292134\ \(0\)\
\-\ be\\:\\ 0\\.0043205138470292755\ \(0\)\
\-\ severe\\:\\ 0\\.004310343934534433\ \(0\)\
\-\ patient\\:\\ 0\\.004212747201228138\ \(0\)\
\-\ from\\:\\ 0\\.004152248239849877\ \(0\)\
\-\ in\\:\\ 0\\.004144890788264803\ \(0\)\
\-\ years\\:\\ 0\\.0041135133393745615\ \(0\)\
\-\ not\\:\\ 0\\.004048585808989952\ \(0\)\
\-\ of\\:\\ 0\\.004010786584848782\ \(0\)\
\-\ all\\:\\ 0\\.0039621696548053946\ \(0\)\
\-\ scan\\:\\ 0\\.003921756492513079\ \(0\)\
\-\ secondary\\:\\ 0\\.003916442568047226\ \(0\)\
\-\ low\\:\\ 0\\.0038953574637154093\ \(0\)\
\-\ an\\:\\ 0\\.0038743110304417373\ \(0\)\
\-\ presented\\:\\ 0\\.0038186190738072282\ \(0\)\
\-\ distal\\:\\ 0\\.0038086534245016833\ \(0\)\
\-\ up\\:\\ 0\\.0037669625427118416\ \(0\)\
\-\ due\\:\\ 0\\.0037381592671358026\ \(0\)\
\-\ signal\\:\\ 0\\.0036935644758570143\ \(0\)\
\-\ mild\\:\\ 0\\.0036889400884116998\ \(0\)\
\-\ than\\:\\ 0\\.003670571893308646\ \(0\)\
\-\ prior\\:\\ 0\\.0035969061839383008\ \(0\)\
\-\ more\\:\\ 0\\.003503567720183879\ \(0\)\
\-\ bone\\:\\ 0\\.0034810404614096227\ \(0\)\
\-\ physical\\:\\ 0\\.003436893884559407\ \(0\)\
\-\ increased\\:\\ 0\\.003427024232458452\ \(0\)\
\-\ \\;\\:\\ 0\\.0033203626040206454\ \(0\)\
\-\ without\\:\\ 0\\.00329838223993141\ \(0\)\
\-\ posterior\\:\\ 0\\.0032289156536105717\ \(0\)\
\-\ mri\\:\\ 0\\.0032184850080567537\ \(0\)\
\-\ findings\\:\\ 0\\.0029816998947376386\ \(0\)\
\-\ right\\:\\ 0\\.0029561695380669398\ \(0\)\
\-\ surgical\\:\\ 0\\.002944625852871235\ \(0\)\
\-\ presents\\:\\ 0\\.002861711959849059\ \(0\)\
\-\ also\\:\\ 0\\.002761671465033035\ \(0\)\
\-\ which\\:\\ 0\\.002614991126627129\ \(0\)\
\-\ a\\:\\ 0\\.0026006544381547625\ \(0\)\
\-\ with\\:\\ 0\\.002109911372112766\ \(0\)\
\-\ was\\:\\ 0\\.001620127085596208\ \(0\)\
\-\ \\.\\:\\ 0\\.0015712909420136875\ \(0\)\
\-\ year\\:\\ 0\\.001567385687332647\ \(0\)\
\-\ old\\:\\ 0\\.0014343190112495977\ \(0\)\
\-\ no\\:\\ 0\\.0014105641814816426\ \(0\)\
\-\ on\\:\\ 0\\.0011867065776482427\ \(0\)\
